- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02052557
The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients who are undergoing elective colon resection with Dr. Kraemer and Dr. Raman will be offered participation in the study. This will include robotic, laparoscopic and open procedures.
In the pre-operative area prior to surgery, the surgical resident will inform the patient of the opportunity to participate in the research study. The resident will consent the patient at that time, if the patient chooses to participate, they will be randomized to an exparel or non-exparel group. The randomization will be done by having the resident pick an envelope that will state whether or not the patient is randomized to the exparel or non-exparel group, this will randomize to 50% in each group. The patient will not be notified of the type of local anesthetic they receive. The attending surgeon will also be blind to the type of local the pt will receive; only the resident and Operating Room (OR) staff will know what type of local anesthetic was given. Unfortunately the opaque color of the exparel precludes the physician injecting the local anesthetic from being blinded to the type of anesthetic given.
The patient will be taken to the operating room as usual, and the surgery will proceed as it normally would. At the end of the surgery the patient will receive either exparel or bupivacaine depending upon which the patient was randomized to. The attending surgeon will not be in the operating suite while the local anesthetic is being injected. 30 milliliters (mL) of either exparel or bupivacaine will be injected into the subcutaneous tissues at the end of surgery.
The patient will be taken to the post operative care unit (PACU), the medications for post-operative pain will be standardized between the two groups, a standard starting dose on the patient controlled analgesia (PCA) will be used, and will be adjusted as needed. The postoperative care will attempt to be standardized in regard to diet, discharge (dc) of foley, not using nasogastric (NG) tubes, however this will be based on the individual patient was what is best for their care. This data will then be analyzed to determine if exparel has a beneficial effect on surgical care.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Iowa
-
Des Moines, Iowa, United States, 50314
- Mercy Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Elective colon resection for both benign and malignant disease
- Laparoscopic, robotic and open techniques
Exclusion Criteria:
- emergent colon cases
- cases preformed by surgeons other than Dr. Raman or Dr. Kraemer
- pregnant patients
- patients currently breast feeding
- patients under the age of 18
- other patients unable to give informed consent
- bupivacaine use within 96 hours
- allergy to amide anesthetics
- prisoners
- caution will be used in patients with renal or hepatic failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Bupivacaine
30 milliliters (ml) of 0.5% marcaine with epinephrine
|
30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
Other Names:
|
Active Comparator: Bupivacaine liposome suspension
exparel 20ml, diluted with 10ml sterile saline for total of 30ml
|
30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PCA (Patient Controlled Analgesia) Usage
Time Frame: 48 hours post operatively
|
Will measure the amount of PCA use for the first 48 hours after surgery.
|
48 hours post operatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oral Pain Medications
Time Frame: 48 hours postoperatively
|
the amount of post operative oral narcotic is measured post op
|
48 hours postoperatively
|
Total IV (Intravenous) Narcotic Used
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days
|
the total amount of IV narcotic is measured that is given during post op period prior to discharge
|
participants will be followed for the duration of hospital stay, an expected average of 3 days
|
Total Oral Narcotic Used
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days
|
participants will be followed for the duration of hospital stay, an expected average of 3 days
|
|
Length of Stay
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days
|
participants will be followed for the duration of hospital stay, an expected average of 3 days
|
|
Return of Bowel Function
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days, and the timing of return of bowel function returning will be recorded
|
participants will be followed for the duration of hospital stay, an expected average of 3 days, and the timing of return of bowel function returning will be recorded
|
|
Readmission
Time Frame: 30 days post operative readmission
|
30 days post operative readmission
|
|
Toradol Use
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days
|
participants will be followed for the duration of hospital stay, an expected average of 3 days
|
|
Ofirmev
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days, and the amount of ofirmev used during admission will be recorded
|
participants will be followed for the duration of hospital stay, an expected average of 3 days, and the amount of ofirmev used during admission will be recorded
|
|
Nausea Medication
Time Frame: The amount of nausea medicine used 48 hours post op was recorded
|
The amount of nausea medicine used 48 hours post op was recorded
|
|
Foley Catheter Removal
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days, the timing of foley catheter removal will be recorded
|
participants will be followed for the duration of hospital stay, an expected average of 3 days, the timing of foley catheter removal will be recorded
|
|
Postoperative Pain
Time Frame: POD #3-5 and POD #13-15
|
The investigators will talk to the patient after surgery immediately post operatively Post Operative Day (POD) #3-5 and POD #13-15 and ask the patients to rate their pain on a scale of 1-10.
|
POD #3-5 and POD #13-15
|
Post Operative Satisfaction
Time Frame: POD #3-5 and POD #13-15
|
The investigators will ask the patient to rate their satisfaction with pain control.
|
POD #3-5 and POD #13-15
|
Home Oral Narcotic Use
Time Frame: POD #13-15
|
The investigators will ask the patients how many of their narcotic pain pills they used after surgery up to the POD #13-15
|
POD #13-15
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NG (Nasogastric) Placement
Time Frame: POD #0 if NG was placed
|
We recorded if an NG was placed immediately post operatively
|
POD #0 if NG was placed
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rachel Knudson, DO, Mercy Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Gastrointestinal Diseases
- Gastroenteritis
- Diverticular Diseases
- Pain, Postoperative
- Diverticulitis
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Anesthetics, Local
- Bupivacaine
Other Study ID Numbers
- MMC2013-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diverticulitis
-
Hospital Central de la Defensa Gómez UllaCompletedDiverticulitis | Diverticulitis Colon | Diverticulitis of Sigmoid | Diverticulitis; Perforation, BowelSpain
-
Sebastiano BiondoRecruiting
-
University of AarhusOdense University Hospital; Aarhus University Hospital; University of Southern... and other collaboratorsRecruiting
-
Ente Ospedaliero Ospedali GallieraCompletedPeritonitis Caused by Perforated Left-sided Colon DiverticulitisItaly
-
Tepecik Training and Research HospitalCompleted
-
Sealantis Ltd.WithdrawnColorectal Cancer | Diverticulitis Colon
-
Uppsala UniversityCompletedColonic DiverticulitisSweden
-
Uppsala UniversityLandstinget i VärmlandCompleted
-
Hospital General Universitario Reina Sofía de MurciaCompletedDiet Modification | Diverticulitis | Dietary Modification | Diverticulitis, Colonic | Acute Diverticulitis | Uncomplicated Diverticular Disease | Diverticulitis of SigmoidSpain
-
Uppsala UniversitySahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Danderyd... and other collaboratorsRecruiting
Clinical Trials on Bupivacaine
-
Hospital Civil de GuadalajaraRecruitingEffect of Subarachnoid Hyperbaric Bupivacaine in Obese Pregnant Patients Undergoing Cesarean SectionAnesthesia | Obstetric Anesthesia ProblemsMexico
-
Hospital Civil de GuadalajaraCompletedAnesthesia, ObstetricalMexico
-
DurectNycomedCompletedPostoperative PainAustria, Germany, Latvia, Poland, Sweden
-
DurectNycomedCompletedPostoperative PainFrance, Germany, Hungary, Latvia, Sweden, United Kingdom
-
Indiana UniversityCompletedPain, Postoperative | Acute Pain | ThoracicUnited States
-
Vanderbilt University Medical CenterCompletedAnesthesia | Breast Reconstruction | Transverse Abdominis Plane BlockUnited States
-
Seoul National University HospitalUnknownAnesthesia, Spinal [E03.155.086.331] | Operating Tables [E07.325.662]Korea, Republic of
-
Coordinación de Investigación en Salud, MexicoInstituto Mexicano del Seguro SocialCompletedObstetric PainMexico
-
Indiana UniversityCompleted
-
University of Texas Southwestern Medical CenterCompleted